Translated data: The British and Swedish pharmaceutical company AstraZeneca has entered into a $247 million agreement with American artificial intelligence (AI) biopharmaceutical company Absci, aimed at collaborating to develop an antibody for combating cancer. Absci will apply generative AI to design the optimal drug candidate, bringing new treatment options to cancer patients. The deal includes an upfront fee, R&D funding, milestone payments, and royalties.